Skip to main content
. 2018 Sep 28;9(76):34398–34412. doi: 10.18632/oncotarget.26146

Table 1. Impact of complex karyotype on OS.

Tot. pts CK Treatment Disease status Median OS
(months)
Univariate analysis Multivariate analysis
Reference CK yes CK no HR (IC 95%) P HR (IC 95%) P
[20] 109 NA various TN and pretreated 107 346 15.44* <0.001 - Ø
[38] 482 71/399
(17.8%)
NA TN 81.1% at 5y 86-94.4%
at 5y #
3.830
(1.714-8.560)
0.001 - Ø
[73] 284 22/182
(12.1%)
FCR R/R 26 10.5 m. -78 m.
##
- - 1.9
(1.1-3.2)
0.015
[74] 80 8/67
(11.9%)
CFAR R/R NA NA - - 2.0
(1.1-3.7)**
0.022
[72] 38 16/38
(42.1%)
NA TN 56 144 - - - -
[39] LC 166
VC 250
20/145 (13.8%)
35/238
(14.7%)
various TN NA NA 2.701
(1.988-8.787)
2.155
(1.160-4.004)
<0.001
0.015
4.856
(1.475-9.998)
3.630
(1.358–9.703)
<0.0001
0.010
[29] 110 38/110
(34.5%)
FCR TN 72.4% at 5 y 85.8% at 5y - - 5.16
(1.2-22.1)
0.07
[24] 161 30/154
(19.5%)
Clb/Clb-R/Clb-G TN NA NA 2.9 (1.5-5.4)°
2.6 (1.3-5.4)°°
0.001°
0.006°°
2.682
(1.366-5.264)
0.004
[63]# 1045 99/1043
(9.5%)
various TN 79 NR - - 1.66
(1.06-2.59)
0.027
[27] 335 41/287
(14.3%)
various TN 70 135 3.176 (1.882-5.359) <0.001 3.572
(1.341-9.515)
0.011
[77] 186 37/186
(19.8%)
Lenalidomide-R
Lenalidomide-O
R/R 23 62.8 - - 2.08
(1.15-3.76)
0.015

TN=treatment naïve; R/R= relapsed/refractory; OS=overall survival; CK=complex karyotype; NA=not available; Clb=chlorambucil; FCR=Fludarabine, Cyclophosphamide, Rituximab; G=Obinutuzumab; R= Rituximab; O-Ofatumumab; Ø=not significant; LC: learning cohort; VC: validation cohort

*log rank; **CK or 17p aberration; °all arms; °°(Clb-R+Clb-G);

#MBL/CLL

# OS was compared in this study between patients with CK and patients without CK carrying chromosome translocations, or 1-2 aberrations or normal karyotype.

## OS in the patients without CK was reported in this study according to the aberration detected by FISH (13q-, +12, 11q-, 17p).